Nxera Pharma announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa's novel orexin receptor 2 (OX2R) agonist, ORX750. The milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial. ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential applicability to narcolepsy type 2 (NT2), idiopathic hypersomnia, and other sleep- wake disorders with normal orexin levels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,605 JPY | +1.07% |
|
+7.36% | +12.95% |
05-31 | Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals | MT |
05-30 | Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.95% | 894M | |
+2.87% | 94.22B | |
-3.42% | 37.76B | |
-13.75% | 32.5B | |
+73.32% | 27.75B | |
-11.88% | 16.13B | |
+0.49% | 14.19B | |
-12.95% | 11.42B | |
+190.36% | 11.06B | |
-54.07% | 9.09B |
- Stock Market
- Equities
- 4565 Stock
- News Nxera Pharma Co., Ltd.
- Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals